Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Placing and Subscription

September 30, 2024
RNS Number : 3313G Renalytix PLC 30 September 2024   THIS ANNOUNCEMENT, INCLUDING THE APPENDICES TO THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,

Re. Results for the fiscal year ended 30 June '24

September 30, 2024
RNS Number : 3303G Renalytix PLC 30 September 2024     Renalytix plc ("Renalytix" or the "Company")   Update on financial results for the fiscal year ended 30 June 2024   LONDON and NEW YORK , 30 September, 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in

Change of Adviser

August 30, 2024
RNS Number : 2027C Renalytix PLC 30 August 2024     Renalytix plc ("Renalytix" or the "Company")   Change of Adviser   LONDON and NEW YORK , 30 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical

Total Voting Rights

August 30, 2024
RNS Number : 2021C Renalytix PLC 30 August 2024     Renalytix plc ("Renalytix" or the "Company")   Total Voting Rights   LONDON  and  NEW YORK , 30 August 2024  -  Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that at today's date, the Company's total issued share capital is   165,925,513

Nasdaq Grants Listing Extension

August 27, 2024
RNS Number : 8219B Renalytix PLC 27 August 2024   Renalytix plc ("Renalytix" or the "Company")   Nasdaq Grants Listing Extension   Renalytix's American Depositary Shares ("ADSs") will continue trading on the Nasdaq Capital Market effective at the open of trading on August 27, 2024   LONDON and NEW

Appointment of Joint Corporate Broker

August 21, 2024
RNS Number : 1687B Renalytix PLC 21 August 2024   Renalytix plc ("Renalytix" or the "Company")   Appointment of Joint Corporate Broker   LONDON and NEW YORK , 21 August 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on

Termination of Formal Sale Process

August 20, 2024
RNS Number : 9865A Renalytix PLC 20 August 2024   Renalytix plc ("Renalytix" or the "Company")   Termination of Formal Sale Process   LONDON and NEW YORK , 20 August 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on

Polar Capital Hldgs - Form 8.3 - RENALYTIX PLC

August 16, 2024
RNS Number : 8107A Polar Capital Holdings PLC 16 August 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of

Polar Capital Hldgs - Form 8.3 - RENALYTIX PLC

August 15, 2024
RNS Number : 6386A Polar Capital Holdings PLC 15 August 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of

Polar Capital Hldgs - Form 8.3 - RENALYTIX PLC

August 13, 2024
RNS Number : 3080A Polar Capital Holdings PLC 13 August 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of
Displaying 11 - 20 of 605